2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2296

Investigation of Environmental Associations of Fibromyalgia Pain Using Twitter Content Analysis
Abstract Number: 2297

Dinamyx Neuromodulation in Fibromyalgia
Abstract Number: 2298

Misdiagnosis of Fibromyalgia (FM) As Axial Spondylarthritis (SpA): Lessons from Analysis of 26 Cases
Abstract Number: 2299

Association Between Catechol-O-Methyl Transferase Gene Polymorphisms and Fibromyalgia in a Korean Population: A Case-Control Study
Abstract Number: 2300

Polymorphisms of Transient Receptor Potential Vanilloid (TRPV) 2 and TRPV3 Gene Polymorphisms Were Associated with Fibromyalgia in a Korean Population
Abstract Number: 2301

Facing Fibromyalgia; How Patients Describe Their Symptoms Based on a Retrospective Evaluation of a Patient Survey and Vitality Assessment in Clinical Trials
Abstract Number: 2302

The Impact of Prior Fibromyalgia Treatment on the Response to Pregabalin in Fibromyalgia Clinical Trials
Abstract Number: 2303

Psychometrics of Online Administration of Fibromyalgia Impact Questionnaire – Revised
Abstract Number: 2304

Clinical, Ultrasonographic and Neurophysiological Correlation of Patients with Carpal Tunnel Syndrome in Santo Domingo, Dominican Republic
Abstract Number: 2305

Relationship Between Anxiety, Depression, Sleep, Fibromyalgia and BMI in Patients with Rheumatic Disease
Abstract Number: 2306

Prevalence of Fibromyalgia in Inflammatory Rheumatic Disease. Single-Center Cross-Sectional Study in 691 Patients
Abstract Number: 2307

Relationship of Sleep Quality and Fibromyalgia Outcomes in a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study of Bedtime, Rapidly Absorbed, Sublingual Cyclobenzaprine (TNX-102 SL)
Abstract Number: 2308

Responder Compared to Mean Change Analyses in a Fibromyalgia Phase 2b Clinical Study of Bedtime Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL)
Abstract Number: 2309

Bedtime, Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia: Results of a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study
Abstract Number: 2310

Evaluation of Fibromyalgia Syndrome in Patients Undergoing Peritoneal Dialysis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].